KaNDy Therapeutics


Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. NT-814 has successfully completed a Phase 2a proof of concept study that demonstrated its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening.

The Phase 2b study, named SWITCH-1, to evaluate the effect of treatment with NT-814 on hot flashes and other symptoms of the menopause was initiated in December 2018. Results from the SWITCH-1 study are expected in late 2019.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.